Marvell Technology agreed to buy Lumentum Holdings for $115 billion in stock, and the market marked both companies down. Marvell fell 12.7% to $171.41 on the day, Lumentum fell 12.5%, and Barron’s put the combined loss of market value at about $91 billion.
The terms, announced Nov. 2, value Lumentum at $1,132 a share, a 23.9% premium to its undisturbed price on Oct. 28. Each Lumentum share converts into 4.5 Marvell shares. When the deal closes, holders of the old Marvell will own 67% of the combined company and Lumentum holders the rest. Closing is scheduled for the first half of 2028.
An acquirer’s stock usually falls when it pays in shares, because the buyer is issuing currency and the market has to absorb more of it. A target’s stock usually rises to trade near the offer, minus a discount for time and risk. Lumentum did neither. It fell almost exactly as much as Marvell, which is not how a deal the market expects to complete is priced.
The symmetry is the interesting part. When a target falls alongside its buyer, investors are not arbitraging a spread between two prices. They are repricing the combined company, and marking down the value of the paper they are being offered. Lumentum holders who accept the exchange are, in effect, taking a position in Marvell, and the drop says they would rather not.
That is the mechanical consequence of a fixed exchange ratio. Once the ratio is set, the value a Lumentum holder receives moves with Marvell’s share price until the vote. Every dollar Marvell loses is a dollar off the offer. If the stock keeps falling, the premium that justified the deal on Oct. 28 erodes, and the board that recommended it has to explain why the price it agreed to is still the right one.
The long runway to closing adds to that exposure. A transaction signed in November for completion in the first half of 2028 gives shareholders and regulators more than a year to examine it, and gives both companies’ trading multiples time to move apart. Deals with that gap are exposed to everything in between: an earnings miss, a change in the cycle, a new antitrust theory, a financing market that closes.
Barron’s raised the question of whether the transaction could fail, and the coverage was framed around that possibility rather than the industrial logic. That framing is itself a market signal. When the financial press asks whether a signed deal will survive, the spread between the offer and the target’s price usually answers it.
The strategic case for combining the two companies rests on components. Marvell designs the silicon that moves data inside and between data centers. Lumentum makes optical parts, the lasers and photonic devices that carry signals over fiber. As computing clusters grow, the bottleneck moves from the processor to the network that connects thousands of them, and optical links become the constraint on how large a cluster can be. Buyers of that equipment care about power per bit and about how far a signal travels before it needs regenerating.
That logic has been the strongest argument in technology dealmaking for two years, and investors have paid for it. The same logic explains why the reaction was harsh. A $115 billion all-stock purchase is a large bet that the optical layer will keep growing faster than the rest of the supply chain, and it is being made with shares whose value has just fallen.
There is also a question of price discipline. The premium was measured against a price four days before the announcement, a window in which the target’s shares could have moved on their own news. Measuring from an undisturbed price is standard practice, but it flatters the number when the reference date is chosen well.
For Marvell’s shareholders, the split matters less than the currency. They keep 67% of a larger company, but the market has already applied a discount to the deal, and the discount is larger than the premium being paid to Lumentum holders. That is an unusual verdict on a transaction no regulator has yet reviewed.
None of this is settled by a single session. Stock deals of this size are approved or rejected on documents that take months to produce, and the price on announcement day reflects a first guess rather than a verdict. What the first guess does establish is the cost of using shares as currency when the market is already doubtful about the sector.
What happens next will be decided in three places: the proxy statement, the antitrust review and the arbitrage desks. The proxy will show what each board knew and when. The review will set the timetable. The desks will decide, day by day, whether the remaining spread is compensation for risk or a warning that the deal is worth less than the paper it is written on.
